Analysis of Voiding Impairment Following Transperineal Prostate Biopsy: Do Alpha-Blockers Reduce the Risk?

Area of Science:

• Urology
• Andrology
• Medical Science

Background:

• Transperineal prostate biopsy (TPPB) can lead to voiding impairment.
• Identifying predictors and preventative measures for post-biopsy voiding dysfunction is crucial.

Purpose of the Study:

• To identify predictors of voiding impairment following TPPB.
• To evaluate the impact of alpha-blocker pretreatment on voiding outcomes after TPPB.

Main Methods:

• A prospective observational study included 279 patients undergoing TPPB.
• Patients were grouped by alpha-blocker pretreatment duration (<12 months vs. none, >12 months vs. none).
• Voiding parameters (IPSS, Qmax, post-void residual) and voiding impairment rates were assessed at 7 and 30 days post-biopsy.

Main Results:

• Alpha-blocker pretreatment for <12 months was associated with significantly lower voiding impairment rates, lower IPSS scores, and higher Qmax at 7 days post-biopsy compared to no pretreatment.
• Pretreatment >12 months showed no significant difference in voiding outcomes.
• Logistic regression identified diabetes mellitus (DM) as an independent predictor of post-biopsy voiding impairment, while alpha-blocker pretreatment for <12 months showed a protective effect.

Conclusions:

• TPPB is associated with a risk of voiding impairment.
• Diabetes mellitus is a significant predictor of post-biopsy voiding impairment.
• Alpha-blocker pretreatment for less than 12 months may offer a protective benefit against voiding impairment after TPPB.